Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Istanbul University |
---|---|
Information provided by: | Istanbul University |
ClinicalTrials.gov Identifier: | NCT00432146 |
Context: Although some of endocrine surgeons administer Lugol's solution to decrease thyroid gland vascularity, there is still no agreement on its effectiveness. Objective: The aims of this clinical trial are to evaluate thyroid blood flow and microvessel density in the patients with Graves' disease according to the Lugol's solution treatment preoperatively.
Design: Retrospective clinical trial. Setting: A tertiary referral center. Method: Thirty-six patients were randomly assigned to preoperative medication with Lugol's solution. Patients in group 1 (n=17) received Lugol's solution for 10 days before surgical intervention, whereas patients in group 2 (n=19) didn't receive it. Main Outcome Measures: Blood flow through the thyroid arteries of patients with Graves' disease was measured by color flow Doppler ultrasonography. The microvessel density (MVD) was assessed immunohistochemically and Western blot analysis using the level of expression of CD-34 in thyroid tissue. The thyroid gland's weight and blood loss were measured in all patients.
Condition | Intervention |
---|---|
Graves Disease |
Drug: lugol's solution |
Study Type: | Observational |
Study Design: | Prospective |
Official Title: | Positive Effect of Lugol's Solution on the Blood Flow and Microvessel Density of Thyroid Gland in the Patients With Graves' Disease |
Estimated Enrollment: | 36 |
Study Start Date: | September 2005 |
Estimated Study Completion Date: | September 2006 |
Thirty-six patients were randomly assigned to preoperative medication with Lugol's solution. Patients in group 1 (n=17) received Lugol's solution for 10 days before surgical intervention, whereas patients in group 2 (n=19) didn't receive it. Blood flow through the thyroid arteries of patients with Graves' disease was measured by color flow Doppler ultrasonography. The microvessel density (MVD) was assessed immunohistochemically and Western blot analysis using the level of expression of CD-34 in thyroid tissue. The thyroid gland's weight and blood loss were measured in all patients.
Ages Eligible for Study: | 14 Years to 61 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 2005/117 |
Study First Received: | February 5, 2007 |
Last Updated: | October 17, 2008 |
ClinicalTrials.gov Identifier: | NCT00432146 History of Changes |
Health Authority: | Turkey: Ethics Committee |
Graves' disease, Lugol's solution |
Goiter Autoimmune Diseases Eye Diseases Graves Disease Endocrine System Diseases Hemostatics Exophthalmos |
Graves' Disease Lugol's solution Orbital Diseases Endocrinopathy Thyroid Diseases Hyperthyroidism |
Goiter Autoimmune Diseases Immune System Diseases Coagulants Eye Diseases Hematologic Agents Graves Disease Endocrine System Diseases |
Pharmacologic Actions Hemostatics Exophthalmos Therapeutic Uses Lugol's solution Orbital Diseases Thyroid Diseases Hyperthyroidism |